Lineage Cell Therapeutics LCTX Institutional Ownership

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is held by 133 institutional investors per 13F filings through June 2026.

• These investors collectively held 44.9% of Lineage Cell Therapeutics's outstanding shares in June 2026, down from 45.6% in March 2026.
• Their total shares held in LCTX increased 11.91% quarter over quarter, and separately, investors owning Lineage Cell Therapeutics increased 4.72% from a year ago.
• Among the 133 funds, 63 bought more Lineage Cell Therapeutics shares, 27 sold down, and 43 held their ground.
• In total, institutional investors held 112.1Mn shares in Lineage Cell Therapeutics as of June 2026, up by 11.93Mn shares quarter on quarter, and up 15.37Mn shares year over year.
• As of June 30, 2026, the biggest holder of Lineage Cell Therapeutics is BROADWOOD CAPITAL INC at 49.56Mn shares, representing 19.86% of shares outstanding.
• The most significant purchases of LCTX for the quarter ending June 2026 came from BlackRock, Inc. (9.32Mn), GEODE CAPITAL MANAGEMENT, LLC (2.78Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (1.27Mn), State Street Corp (1.22Mn), Northern Trust Corp (1.16Mn).
• The largest sales of LCTX for the quarter ending June 2026 came from MILLENNIUM MANAGEMENT LLC (2.54Mn), MARSHALL WACE, LLP (1.78Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.24Mn), JANE STREET GROUP, LLC (943.42K), RENAISSANCE TECHNOLOGIES LLC (780.27K).
• Per Business Quant data, the top 10 holders of Lineage Cell Therapeutics for the quarter ending June 2026 are BROADWOOD CAPITAL INC (49.56Mn), BlackRock, Inc. (13.19Mn), VANGUARD CAPITAL MANAGEMENT LLC (9.05Mn), Defender Capital, LLC. (6.6Mn), GEODE CAPITAL MANAGEMENT, LLC (5.3Mn), Fifth Third Bancorp (4.6Mn), MILLENNIUM MANAGEMENT LLC (3.02Mn), State Street Corp (2.31Mn), VANGUARD FIDUCIARY TRUST CO (1.67Mn), Northern Trust Corp (1.66Mn).